Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
RAD216 ADVANCED IMAGING MODALITIES BONE DENSITOMETRY INTRODUCTION Over the last 50+ years, medical imaging has been at the forefront in the development of ways to better diagnose bone mineral loss. This bone loss is called osteopenia or osteoporosis. HISTORY Until the 1960s radiologists could only make a diagnosis of bone mineral loss by analyzing radiographic images. Visible loss of bony trabecula usually meant a bone loss of between 30% and 50%. A more sensitive quantitative method was needed to determine bone mineral loss. 1 HISTORY Bone densitometry had its origins in nuclear medicine in the 1960s. It was called single photon absorptiometry (SPA). It used iodine-125 which emitted 35 keV gamma rays. HISTORY The use of an x-ray tube instead of a gamma ray source introduced singleenergy x-ray absorptiometry (SXA). The x-ray beam was heavily filtered in order to produce a near homogeneous beam (hence the term “single energy”). 2 HISTORY The 1970s saw the introduction of dual photon absorptiometry (DPA). This technique used a radioactive source that could emit gamma radiation in two energies. Gadolinium-153 emits gamma rays with energies of 44 and 100 keV. HISTORY In the 1980s dual-energy x-ray absorptiometry (DXA) becomes the radiographic extension of DPA. Modern systems use a “fan beam” configuration. Dual energies are achieved by the use of beam filtering or variation of generator output. HISTORY Around the same time, CT finds application in bone densitometry, called quantitative computed tomography (QCT). However, the use of CT for this purpose is costly, requiring more radiation and no more accurate than DXA. 3 HISTORY The use of ultrasound to perform bone density measurements has been around since the 1960s, but has yet to achieve the degree of precision provided by DXA. This method is called quantitative ultrasound (QUS). BONE DENSITOMETRY Various methods to measure bone mineral content in order to accurately diagnose osteoporosis. OSTEOPOROSIS A condition involving loss of bone mineral density to the extent defined by the World Health Organization (WHO). 4 OSTEOPOROSIS The WHO defines osteoporosis on the basis of statistical comparison with historical data. The computation of scores is compared to a standard. OSTEOPOROSIS The bone densitometry procedure produces 4 important values: Bone mineral content Bone mineral density T score Z score BONE MINERAL CONTENT (BMC) The amount of mineralization present in a given volume of bone and measured in grams (g). 5 BONE MINERAL DENSITY A derived unit indicating the concentration of mineralization present per square centimeter (g/cm2). T-SCORE A calculation based on comparison with an average person of young age and peak bone mineralization. The score is a normalized value that ranges from -3 to +3 standard deviations. Z-SCORE A calculation based on a comparison with an average person of the same age and sex. 6 T-SCORE & OSTEOPOROSIS Of the four values, the t-score is the most significant. According to the WHO, a patient whose t-score falls below -2.5 is considered to have osteoporosis. T-SCORE & OSTEOPENIA As defined by the WHO, a patient with a score in the range of -1.0 and -2.5 is said to have osteopenia, an intermediate level of bone mineral density loss. 7 BONE PHYSIOLOGY Bone is a living tissue in constant state of breakdown and repair. Bone cells called osteoblasts and osteoclasts are involved in the repair and breakdown process, respectively. Certain conditions cause the rate of breakdown to exceed the rate of repair, resulting in net bone loss due to resorption. RISK FACTORS (AND INDICATIONS) Post menopausal women are potentially at risk if they have one or more of the following risk factors: Family history History of fractures Smoking Alcohol consumption Low body weight Sedentary lifestyle Low calcium & vitamin D intake Taking certain medications (corticosteroids, thyroid replacement, Dilantin, etc.) CONTRAINDICATIONS Pregnancy Deformities of anatomy to be scanned Previous fracture at site to be scanned Excessive body part thickness 8 PATIENT PREPARATION Patients only need to wear loosefitting clothing (gown preferred) with no metallic objects such as zippers to obscure anatomy. PATIENT PREPARATION NO CALCIUM SUPPLEMENTS FOR 24 HOURS BEFORE EXAM IF CONTRAST STUDY PERFORMED, MUST WAIT 10-14 DAYS BEFORE DXA PERFORMED WAIT 10-14 DAYS POST CT OR NUCLEAR MEDICINE STUDY SELECTION OF ANATOMY Patient history usually determines what anatomy is examined. For most DXA procedures, the lumbar spine or proximal femur (hip) is examined (called central axis imaging). Peripheral imaging of the elbow, wrist, finger, lower leg and calcaneus can also be examined by DXA using dedicated peripheral units. 9 SELECTION OF ANATOMY Only anatomy that is not fractured or deformed should be evaluated in order to obtain the most accurate results. LUMBAR SPINE Patient lies on back with legs supported. A scout (pilot) image is obtained and the vertebrae selected (usually L1 or L2 through L4). 10 HIP The patient lies with the midsagittal plane aligned with the midline of the table. Legs are extended and feet inverted 15 to 20 degrees. A pilot image is obtained of the hip and proximal femur. The femur should be parallel to the long axis of the image. QUANTITATIVE ULTRASOUND Usually performed on peripheral structures (toe, calcaneus, finger). 11 POSTPROCEDURE INSTRUCTIONS Patients do not require any special instructions, but should check back with their referring physician to obtain results. TECHNOLOGY UPDATE Hologic®, a manufacturer of DXA equipment, introduced the Discovery QDR™ series of scanners. 12 Discovery QDR features High-definition Instant Vertebral Assessment (IVA) to visually evaluate lumbar deformities CADfx uses software to quantify vertebral deformities Hip Structure Analysis (HSA) to evaluate structural geometry Measurement of possible coronary artery disease (FDA approved) 13